British drugmaker GlaxoSmithKline Plc is planning a restructuring of its U.S. operations that could include hundreds of job cuts, possibly affecting New Jersey employees.
Multiple published reports say Glaxo could announce details of the restructuring as soon as this week, with Deirdre Connelly, president of North American operations, scheduled to speak to workers Wednesday.
Glaxo has struggled with sales of respiratory medicines in the U.S., the reports said, putting pressure on the North American unit.
“Each business unit is currently deciding how to respond to this challenge,” Glaxo said in a statement. “When we do have proposals, we will first share those with our employees.”
Glaxo employs a combined 5,000 workers in New Jersey and Pennsylvania, according to the reports.
In October, Glaxo had announced the restructuring as part of its quarterly earnings news, saying:
“We … intend to refocus our global pharmaceuticals business and cost base following the divestiture of our oncology products and the changed dynamics we now face in the U.S. respiratory market. This new restructuring programme will rescale commercial operations, global support functions and relevant R&D/manufacturing across pharmaceuticals and is expected to deliver cost savings incremental to the existing announced programmes.”
ALSO ON NJBIZ: